Alejandra Mendoza retweeted
Finally, a global consensus on #ACLF criteria and severity !
It will help large-scale observational studies and better international clinical trials.
@EASLnews @AASLDtweets @APASLnews @alehlatam @Solda_Society
Alejandra Mendoza retweeted
Pancreatitis, just like liver disease and IBD, appears to have a progressive spectrum of phenotypes ranging from acute inflammatory to chronic fibrotic.
This study in @UEGJournal proposes an early chronic pancreatitis (ECP) phenotype, which could be a critical window for intervention to prevent irreversible damage.
📸: onlinelibrary.wiley.com/doi/…
Alejandra Mendoza retweeted
Evolución de los objetivos terapéuticos en la enfermedad inflamatoria intestinal (#EII):
👉 STRIDE 1 (2015)
👉 STRIDE 2 (2021)
👉 STRIDE 3 (2026)
📊 Todas las diferencias clave, resumidas en una única tabla. 👇
Alejandra Mendoza retweeted
Dyssynergic defecation in and of itself can slow gastric emptying via the cologastric brake. Many patients given a label of gastroparesis actually have DD!
🚨 Our new study in @DDS_Journal highlights an overlooked issue #Gastroparesis!
🔍 Nearly 30% of the patients had constipation, yet defecatory disorders were rarely diagnosed and biofeedback therapy was markedly underused.
📉 Patients who underwent ARM had lower odds of hospitalizations, ED visits & abdominal imaging.
🔗 link.springer.com/article/10…
Alejandra Mendoza retweeted
IBS & the gut–brain axis: key takeaways from The Lancet
• ~1 in 5 people have IBS, chronic constipation or functional diarrhoea combined.
• Diagnostic criteria matter: IBS prevalence is 4.1% with Rome IV vs 8.5% with Rome V.
• ~15% develop IBS after infectious enteritis.
• Make a positive diagnosis: symptom assessment, alarm features and targeted investigations.
• Low-FODMAP has the strongest dietary evidence—follow restriction with reintroduction and personalisation.
• Treat the predominant symptom: constipation, diarrhoea, pain or bloating. Brain–gut behaviour therapies also have a role.
• Set realistic expectations: most treatments improve symptoms in fewer than 50% of patients.
Black et al. The Lancet, 2026
doi.org/10.1016/S0140-6736(2…
Alejandra Mendoza retweeted
Dosis de los medicamentos (incluidos los tratamientos biológicos) para la enfermedad inflamatoria intestinal (#EII)
Por la Dra. @Bealoquebea
Alejandra Mendoza retweeted
Evolution of treatment targets in #IBD:
👉Stride 1 (2015)
👉Stride 2 (2021)
👉Stride 3 (2026)
Key differences, all in one table 👇
Alejandra Mendoza retweeted
Upadacitinib was linked to a lower risk of treatment failure than five other advanced therapies for #ulcerativecolitis, especially among patients who had used an advanced therapy in the previous 12 months, in a new study from @AGA_CGH.
➡️ow.ly/G8bh5101nEg
Alejandra Mendoza retweeted
Roemheld syndrome on one sheet: bloating, then thoracic pain, then presyncope.
A large hiatal hernia, pathologic reflux, and a symptom association probability of 99.3%.
Alejandra Mendoza retweeted
⭐️ Propuesta para caracterizar los trastornos gastroduodenales mediante mapeo eléctrico gástrico de superficie.
La Clasificación de Auckland define distintos fenotipos a partir del body surface gastric mapping, con el objetivo de mejorar la caracterización fisiológica de estos pacientes y avanzar hacia una evaluación más precisa de los trastornos gastroduodenales.
🔬 Una herramienta con potencial para refinar el diagnóstico y la estratificación clínica.
onlinelibrary.wiley.com/doi/…
#Gastroenterología #Motilidad #Gastroduodenal #GITwitter
Alejandra Mendoza retweeted
💡 JAMA Insights: #CeliacDisease is an autoimmune disease triggered by dietary gluten and affects at least 1% of the global population. Diagnosis should be performed while patients are consuming gluten, with tissue transglutaminase IgA testing and total serum IgA used as first-line screening to support accurate detection.
A serology-based diagnosis may be appropriate in selected children and adults with tissue transglutaminase IgA levels ≥10 the upper limit of normal. Biopsy remains important for patients with IgA deficiency, alarm symptoms, certain autoimmune disorders, or certain chromosomal disorders.
ja.ma/3VIdc2h
Alejandra Mendoza retweeted
🧬 New UK consensus | Lynch syndrome beyond CRC/endometrial cancer
🧪 dMMR/MSI tumors
✅ Upfront germline testing: urinary tract, small bowel, pancreas, adrenal, sebaceous & glioma
🔬 Gastric: MLH1 methylation triage
🎯 Tailored testing pathways
🔗 doi.org/10.1136/jmg-2026-111…
@OncoAlert
Alejandra Mendoza retweeted
What happens in the rectal mucosa before — and potentially as part of — perianal fistulising Crohn’s disease?
Gudiño et al. present “TL1A-activated T cells remodel the rectal mucosa in patients with Crohn’s disease with perianal fistulising disease” via bit.ly/3V1eEMH
Using single-cell RNA sequencing of rectal biopsies from patients with Crohn’s disease with and without perianal fistulising disease, together with functional studies in T cells, tissue explants, fibroblasts and epithelial cultures, this study identifies a distinct molecular signature associated with fistulising disease.
The rectal mucosa of patients with perianal fistulising disease showed cellular and transcriptional alterations that were independent of luminal inflammation. The researchers implicate TL1A activation in CD4+ T cells and identify lymphotoxin β and IL-22 as downstream mediators affecting fibroblast and epithelial compartments.
Importantly, the TL1A–LTα1β2/IL-22 pathway operates independently of TNF signalling, suggesting that these molecular changes may persist even in the context of anti-TNF therapy.
The findings provide new insight into the mechanisms that may predispose to perianal fistulising disease and support further investigation of TL1A-directed approaches in this challenging complication of Crohn’s disease.
#CrohnsDisease #PerianalDisease #TL1A
Alejandra Mendoza retweeted
Today is packed on the IBD track - one of the most important conference days for IBD I can remember.
You can't see everything unless you clone yourself ** ...
so head to UEG forum for 10am
• VERDICT primary outcome *
• STRIDE-III *
• FUZION 48w *
• ABBV-466
starring Vip, Axel, Ailsa and Remo
* first look at all of these (still under embargo)
** if the cloning worked go to D3 for obefazimod ph3 maintenance data (already in the public domain)
THEN ... 1130am to A2 for the 5y Profile data (or just read the paper @LancetGastroHep ) and 1150am to A1 for IBD nutrition matters
230pm Lessons from large IBD real-world cohorts (A1)
4pm Teaching an old dog new tricks: New implementations of current IBD drugs (A1) including AFFIRM-UC (sc risa induction) and DIRECT-CD (sc ifx induction) and much more.
Oh, there are a bunch of live poster sessions too!
THEN ... come to the @my_ueg night and drink a beer with me.
Alejandra Mendoza retweeted
1/5 🏀 Next up: Bridging, Downstaging, and Immunotherapy Before Transplant for HCC
Elizabeth Williams explores how treatment before transplant can help patients reach transplantation, and the risks we need to consider.
Thread 👇 #HepMadness2026
Alejandra Mendoza retweeted
¿Conoces los mecanismos de acción de los tratamientos para la #EII?
Desde las terapias ya aprobadas hasta las moléculas actualmente en investigación, el abordaje terapéutico de la enfermedad inflamatoria intestinal continúa ampliándose con nuevas dianas y mecanismos de acción.
🔬 Una visión global para entender dónde actúa cada tratamiento y hacia dónde se dirige el futuro terapéutico de la EII. nature.com/articles/s41575-0…
#EII #Gastroenterología #MedTwitter #GITwitter
Alejandra Mendoza retweeted
🦠 ¿Puede un probiótico ayudar a mantener la respuesta tras rifaximina en pacientes con SII-D?
Nuevos datos sugieren que, tras una respuesta favorable a rifaximina, el uso de un probiótico multicepa podría reducir la recurrencia de los síntomas.
🔬 Un enfoque interesante para prolongar el beneficio clínico y explorar nuevas estrategias de mantenimiento en el síndrome del intestino irritable con diarrea.
#SII #IBSD #Microbiota #Probióticos #Gastroenterología
Alejandra Mendoza retweeted
The changes in STRIDE-III 👏🏼 #UEGWeek
Alejandra Mendoza retweeted
Management of Colonic Pseudoobstruction (Ogilvie's)
Ref: ASGE Guidelines 2020
Alejandra Mendoza retweeted
📰 New review in the November issue of Frontline Gastroenterology
Abuquteish et al review lower GI toxicity from immune checkpoint inhibitors and targeted cancer therapies, covering clinical, endoscopic and histological features.
🔑 Anti-CTLA-4 causes earlier and more severe colitis than anti-PD-1/PD-L1, and colitis was reported in about 25% of patients on combined ipilimumab and nivolumab. Rituximab was linked to a roughly sixfold increased risk of developing IBD.
🔗 doi.org/10.1136/flgastro-202…
@BritSocGastro @dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @dtleiberman

ALT The image is an informational chart about medications used in treating inflammatory bowel disease (IBD). It is divided into two sections: "Immune Checkpoint Inhibitors (ICI)" and "Targeted therapies." The ICI section includes anti-PD1/PDL-1 medications such as nivolumab and pembrolizumab, and anti-CTLA-4 medication like ipilimumab. The targeted therapies section lists anti-CD20 drugs like rituximab, and BRAF and MEK inhibitors including dabrafenib and trametinib. Each listing describes the medication's effects, common complications, and their association with IBD.










































